| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6399632 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US6187791 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
| US5578610 | CHATTEM SANOFI | Piperidine derivatives |
Nov, 2013
(10 years ago) | |
| US7138524 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| US7135571 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
|
US5578610 (Pediatric) | CHATTEM SANOFI | Piperidine derivatives |
May, 2014
(9 years ago) | |
|
US7138524 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
|
US7135571 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
| US5932247 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5855912 | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(9 years ago) | |
| US6113942 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5738872 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
|
US5855912 (Pediatric) | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5932247 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US6113942 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
| US6037353 | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) | |
|
US6037353 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(6 years ago) | |
| US6723348 | CHATTEM SANOFI | Orodispersible tablets containing fexofenadine |
Nov, 2021
(2 years ago) | |
| US8933097 | CHATTEM SANOFI | Fexofenadine suspension formulation |
Aug, 2030
(6 years from now) | |
Children'S Allegra Allergy is owned by Chattem Sanofi.
Children'S Allegra Allergy contains Fexofenadine Hydrochloride.
Children'S Allegra Allergy has a total of 19 drug patents out of which 18 drug patents have expired.
Expired drug patents of Children'S Allegra Allergy are:
- US6399632*PED
- US6187791*PED
- US5578610
- US7138524
- US7135571
- US5578610*PED
- US7138524*PED
- US7135571*PED
- US5932247
- US5855912
- US6113942
- US5738872
- US5855912*PED
- US5932247*PED
- US6113942*PED
- US6037353
- US6037353*PED
- US6723348
Children'S Allegra Allergy was authorised for market use on 24 January, 2011.
Children'S Allegra Allergy is available in tablet;oral, tablet, orally disintegrating;oral, suspension;oral dosage forms.
Children'S Allegra Allergy can be used as relief of symptoms associated with respiratory allergies adults and children 6 years of age and older, relief of symptoms associated with respiratory allergies and for the relief of symptoms associated with hives (urticaria) in adults and children 6 years of age and older, relief of symptoms associated with respiratory allergies and for the relief of symptoms associated with hives (urticaria) in adults and children 6 years of age and older and 12 years of age and older.
The generics of Children'S Allegra Allergy are possible to be released after 02 August, 2030.
Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2011
Treatment: Relief of symptoms associated with respiratory allergies and for the relief of symptoms associated with hives (urticaria) in adults and children 6 years of age and older; Relief of symptoms associated...
Dosage: TABLET;ORAL; SUSPENSION;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL
CHILDREN'S ALLEGRA ALLERGY family patents
